Cargando…
Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/ https://www.ncbi.nlm.nih.gov/pubmed/32974448 http://dx.doi.org/10.1093/ehjcr/ytaa103 |
_version_ | 1783584123815723008 |
---|---|
author | Jiménez-Marrero, Santiago Enjuanes, Cristina Yun, Sergi Comín-Colet, Josep |
author_facet | Jiménez-Marrero, Santiago Enjuanes, Cristina Yun, Sergi Comín-Colet, Josep |
author_sort | Jiménez-Marrero, Santiago |
collection | PubMed |
description | BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyperkalaemia, which often limits the optimization of recommended, Class I treatments. In this context, potassium binders patiromer or sodium zirconium cyclosilicate (ZS-9) provide an opportunity to optimize the pharmacological management of these patients. CASE SUMMARY: We present a case report illustrating our real-life experience using the potassium-binder patiromer in a patient with HFrEF, in whom recurrent hyperkalaemia (up to 6.3 mmol/L with low doses of enalapril) was preventing titration of RAAS inhibition therapies. Use of patiromer allowed re-introducing ramipril (subsequently switched to sacubitril/valsartan) and eplerenone. Serum potassium levels remained normal with patiromer 16.8 g/24 h, and the patient’s tolerance to patiromer was excellent. DISCUSSION: In patients with HFrEF and recurrent hyperkalaemia, optimal RAAS inhibition is often discontinued. In this context, novel potassium binders such as patiromer or ZS-9 have been shown to be effective in lowering potassium and maintaining normokalaemia, with a good safety profile and patient tolerance, all of which make them promising alternative options. Our preliminary experience suggests that patiromer may be a helpful and well-tolerated treatment option, which may aid in achieving optimal RAAS inhibition in HFrEF patients with recurrent hyperkalaemia. Registries of HFrEF patients will help better understand whether therapies such as patiromer have prognostic benefits through facilitating optimal RAAS blockade. |
format | Online Article Text |
id | pubmed-7501904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75019042020-09-23 Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report Jiménez-Marrero, Santiago Enjuanes, Cristina Yun, Sergi Comín-Colet, Josep Eur Heart J Case Rep Case Reports BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyperkalaemia, which often limits the optimization of recommended, Class I treatments. In this context, potassium binders patiromer or sodium zirconium cyclosilicate (ZS-9) provide an opportunity to optimize the pharmacological management of these patients. CASE SUMMARY: We present a case report illustrating our real-life experience using the potassium-binder patiromer in a patient with HFrEF, in whom recurrent hyperkalaemia (up to 6.3 mmol/L with low doses of enalapril) was preventing titration of RAAS inhibition therapies. Use of patiromer allowed re-introducing ramipril (subsequently switched to sacubitril/valsartan) and eplerenone. Serum potassium levels remained normal with patiromer 16.8 g/24 h, and the patient’s tolerance to patiromer was excellent. DISCUSSION: In patients with HFrEF and recurrent hyperkalaemia, optimal RAAS inhibition is often discontinued. In this context, novel potassium binders such as patiromer or ZS-9 have been shown to be effective in lowering potassium and maintaining normokalaemia, with a good safety profile and patient tolerance, all of which make them promising alternative options. Our preliminary experience suggests that patiromer may be a helpful and well-tolerated treatment option, which may aid in achieving optimal RAAS inhibition in HFrEF patients with recurrent hyperkalaemia. Registries of HFrEF patients will help better understand whether therapies such as patiromer have prognostic benefits through facilitating optimal RAAS blockade. Oxford University Press 2020-06-28 /pmc/articles/PMC7501904/ /pubmed/32974448 http://dx.doi.org/10.1093/ehjcr/ytaa103 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Case Reports Jiménez-Marrero, Santiago Enjuanes, Cristina Yun, Sergi Comín-Colet, Josep Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
title | Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
title_full | Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
title_fullStr | Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
title_full_unstemmed | Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
title_short | Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
title_sort | use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/ https://www.ncbi.nlm.nih.gov/pubmed/32974448 http://dx.doi.org/10.1093/ehjcr/ytaa103 |
work_keys_str_mv | AT jimenezmarrerosantiago useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport AT enjuanescristina useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport AT yunsergi useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport AT comincoletjosep useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport |